** charts after earnings **
Amyris misses by $0.46, misses on revs
- Reports Q3 (Sep) loss of $0.63 per share, excluding non-recurring items, $0.46 worse than the two analyst estimate of ($0.17); revenues fell 38.4% year/year to $14.9 mln vs the $46.72 mln two analyst estimate.
- "We are pleased with the rapid ramp up of our new, zero calorie sweetener product and our continued strong recurring revenue growth," said John Melo, President and CEO of Amyris. "However, we are very disappointed with the volatility of the Vitamin E market and its direct impact on our third quarter revenue. Some of this shortfall is expected be made up with our core market revenue performance through year end." Continued Melo, "While the unpredictable nature of the Vitamin E market and our royalty is disappointing, we are very pleased by the strong growth of our Clean Beauty business, the early demand for our zero calorie sweetener and for the better than planned growth of our ingredients business. Our recurring revenue has been doubling year on year and we are on pace to deliver for the fourth quarter at an annualized rate of about $200 million in recurring revenue.
No comments:
Post a Comment